|
Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.
The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.
Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.
Investment Considerations:
- Imagin Medical Inc. uses the standard levels of care for bladder tumor resection and adds advanced technology combined with an FDA-approved imaging agent to display images side-by-side in real-time to provide better cancer visualization, potentially leading to less recurrence.
- Hospitals can use their existing endoscopic equipment, as the company’s technology is compatible with almost every model on the market.
- The i/Blue™ Imaging System can potentially be used for other minimally invasive procedures, accommodating multiple contrast agents and illumination sources.
- Bladder cancer contributes to 4.5% of all new cancers diagnosed and 3% of all cancer-related deaths. It is the sixth most prevalent form of cancer in the United States, with a greater than 50% risk of recurrence.
- The company is led by a management team with experience in this industry, including minimally invasive surgery and medical device implementation.
|
